Novel generation of agents with proven clinical activity in multiple myeloma

Seminars in Oncology

Volumn 40, Issue 5, 2013, Pages 618-633

  Mateos, María Victoria ^a   Ocio, Enrique M ^a   San Miguel, Jesús F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IXAZOMIB; IXAZOMIB CITRATE; LENALIDOMIDE; MELPHALAN; OPROZOMIB; POMALIDOMIDE; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; THALIDOMIDE;

ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DIARRHEA; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; KIDNEY FAILURE; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PLASMA CELL DYSCRASIA; PNEUMONIA; PRIORITY JOURNAL; THERAPY EFFECT; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; LACTONES; MULTIPLE MYELOMA; OLIGOPEPTIDES; PROTEASOME INHIBITORS; PYRROLES; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84886894440     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.07.005     Document Type: Article

References (112)

1. S.K. Kumar, S.V. Rajkumar, and A. Dispenzieri Improved survival in multiple myeloma and the impact of novel therapies Blood 111 5 2008 2516 2520
2. A.P. Arrigo, K. Tanaka, A.L. Goldberg, and W.J. Welch Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome) Nature 331 6152 1988 192 194
3. J. Adams, V.J. Palombella, and E.A. Sausville Proteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res 59 11 1999 2615 2622
4. T. Hideshima, P. Richardson, and D. Chauhan The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Res 61 7 2001 3071 3076
5. R. LeBlanc, L.P. Catley, and T. Hideshima Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model Cancer Res 62 17 2002 4996 5000
6. P.G. Richardson, B. Barlogie, and J. Berenson A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 26 2003 2609 2617
7. P.G. Richardson, P. Sonneveld, and M.W. Schuster Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 24 2005 2487 2498
8. P.G. Richardson, P. Sonneveld, and M. Schuster Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial Blood 110 10 2007 3557 3560
9. A.J. Rivett, and A.R. Hearn Proteasome function in antigen presentation: immunoproteasome complexes, peptide production, and interactions with viral proteins Curr Protein Pept Sci 5 3 2004 153 161
10. A. Ciechanover, and A.L. Schwartz The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death Proc Natl Acad Sci U S A 95 6 1998 2727 2730
11. N. Mitsiades, C.S. Mitsiades, and V. Poulaki Molecular sequelae of proteasome inhibition in human multiple myeloma cells Proc Natl Acad Sci U S A 99 22 2002 14374 14379
12. T. Hideshima, C. Mitsiades, and M. Akiyama Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341 Blood 101 4 2003 1530 1534
13. T. Hideshima, P.G. Richardson, and K.C. Anderson Targeting proteasome inhibition in hematologic malignancies Rev Clin Exp Hematol 7 2 2003 191 204
14. P. Carvalho, V. Goder, and T.A. Rapoport Distinct ubiquitin-ligase complexes define convergent pathways for the degradation of ER proteins Cell 126 2 2006 361 373
15. S. Raasi, and D.H. Wolf Ubiquitin receptors and ERAD: a network of pathways to the proteasome Semin Cell Dev Biol 18 6 2007 780 791
16. M. Karin How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex Oncogene 18 49 1999 6867 6874
17. J. Adams Development of the proteasome inhibitor PS-341 Oncologist 7 1 2002 9 16
18. M. Altun, P.J. Galardy, and R. Shringarpure Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells Cancer Res 65 17 2005 7896 7901
19. P. Moreau, H. Pylypenko, and S. Grosicki Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study Lancet Oncol 12 5 2011 431 440
20. R.Z. Orlowski, T.E. Stinchcombe, and B.S. Mitchell Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies J Clin Oncol 20 22 2002 4420 4427
21. S. Jagannath, B. Barlogie, and J. Berenson A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Br J Haematol 127 2 2004 165 172
22. S.V. Rajkumar, P.G. Richardson, T. Hideshima, and K.C. Anderson Proteasome inhibition as a novel therapeutic target in human cancer J Clin Oncol 23 3 2005 630 639
23. R.Z. Orlowski, A. Nagler, and P. Sonneveld Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J Clin Oncol 25 25 2007 3892 3901
24. N. Mitsiades, C.S. Mitsiades, and P.G. Richardson The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications Blood 101 6 2003 2377 2380
25. P.G. Richardson, E. Weller, and S. Lonial Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma Blood 116 5 2010 679 686
26. A.J. Jakubowiak, K.A. Griffith, and D.E. Reece Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial Blood 118 3 2011 535 543
27. P.G. Richardson, E. Weller, and S. Jagannath Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma J Clin Oncol 27 34 2009 5713 5719
28. J.L. Harousseau, M. Attal, and H. Avet-Loiseau Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial J Clin Oncol 28 30 2010 4621 4629
29. P. Sonneveld, I. Schmidt-Wolf, and B. van der Holt HOVON-65/GMMG-HD4 Randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM) ASH Annual Meeting Abstracts 116 21 2010 40
30. M. Cavo, P. Tacchetti, and F. Patriarca Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study Lancet 376 9758 2010 2075 2085
31. L. Rosinol, M.T. Cibeira, and M.V. Mateos A phase III PETHEMA/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: superiority of VTD (bortezomib/thalidomide/dexamethasone) over TD and VBMCP/VBAD plus bortezomib ASH Annual Meeting Abstracts 116 21 2010 307
32. J.F. San Miguel, R. Schlag, and N.K. Khuageva Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 9 2008 906 917
33. M.V. Mateos, A. Oriol, and J. Martinez-Lopez Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial Lancet Oncol 11 10 2010 934 941
34. A. Palumbo, S. Bringhen, and D. Rossi Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial J Clin Oncol 28 34 2010 5101 5109
35. D.J. Kuhn, Q. Chen, and P.M. Voorhees Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma Blood 110 9 2007 3281 3290
36. S.D. Demo, C.J. Kirk, and M.A. Aujay Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome Cancer Res 67 13 2007 6383 6391
37. O.A. O'Connor, A.K. Stewart, and M. Vallone A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies Clin Cancer Res 15 22 2009 7085 7091
38. M. Alsina, S. Trudel, and R.R. Furman A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma Clin Cancer Res 18 17 2012 4830 4840
39. S. Jagannath, R. Vij, and A.K. Stewart An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma Clin Lymphoma Myeloma Leuk 12 5 2012 310 318
40. D.S. Siegel, T. Martin, and M. Wang A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma Blood 120 14 2012 2817 2825
41. R. Vij, M. Wang, and J.L. Kaufman An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma Blood 119 24 2012 5661 5670
42. P. Squifflet, S. Michiels, D.S. Siegel, R. Vij, S. Ro, and M.E. Buyse Multivariate modelling reveals evidence of a dose-response relationship in phase 2 studies of single-agent carfilzomib ASH Annual Meeting Abstracts 118 21 2011 1877
43. R. Vij, D.S. Siegel, and S. Jagannath An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib Br J Haematol 158 6 2012 739 748
44. A.J. Jakubowiak, D.S. Siegel, and S. Singhal Unfavorable cytogenetic characteristics do not adversely impact response rates in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib on the 003 (A1) study ASH Annual Meeting Abstracts 118 21 2011 1875
45. A.Z. Badros, R. Vij, and T. Martin Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety Leukemia 2013 Aug;27(8):1707-14
46. S. Singhal, D.S. Siegel, and T. Martin Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis ASH Annual Meeting Abstracts 118 21 2011 1876
47. M. Wang, W. Bensinger, and T. Martin Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM) ASCO Meeting Abstracts 29 15 suppl 2011 8025
48. A.J. Jakubowiak, D. Dytfeld, and K.A. Griffith A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma Blood 120 9 2012 1801 1809
49. P. Sonneveld, E. Hacker, and S. Zweegman Carfilzomib combined with thalidomide and dexamethasone (CARTHADEX) as induction treatment prior to high-dose melphalan (HDM) in newly diagnosed patients with multiple myeloma (MM). A trial of the European Myeloma Network EMN ASH Annual Meeting Abstracts 118 21 2011 633
50. P. Moreau, A.P. Palumbo, and A.K. Stewart A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM) ASCO Meeting Abstracts 29 15 suppl 2011 TPS225
51. H.J. Zhou, M.A. Aujay, and M.K. Bennett Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047) J Med Chem 52 9 2009 3028 3038
52. K.P. Papadopoulos, D.S. Mendelson, and A.W. Tolcher A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors ASCO Meeting Abstracts 29 15 suppl 2011 3075
53. M.R. Savona, J.G. Berdeja, and S.J. Lee A phase 1b dose-escalation study of split-dose oprozomib (ONX0912) in patients with hematologic malignancies ASH Annual Meeting Abstracts 120 21 2012 203
54. D. Chauhan, Z. Tian, and B. Zhou In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells Clin Cancer Res 17 16 2011 5311 5321
55. N. Gupta, M. Saleh, and K. Venkatakrishnan Flat-dosing versus BSA-based dosing for MLN9708, an investigational proteasome inhibitor: population pharmacokinetic (PK) analysis of pooled data from 4 phase-1 studies ASH Annual Meeting Abstracts 118 21 2011 1433
56. S. Kumar, W.I. Bensinger, and C.B. Reeder Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma: results from a phase 1 dose-escalation study ASH Annual Meeting Abstracts 118 21 2011 816
57. P.G. Richardson, R. Baz, and L. Wang Investigational agent MLN9708, an oral proteasome inhibitor, in patients (Pts) with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study ASH Annual Meeting Abstracts 118 21 2011 301
58. S.K. Kumar, J.G. Berdeja, and R. Niesvizky A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM) ASH Annual Meeting Abstracts 120 21 2012 332
59. J.G. Berdeja, P.G. Richardson, and S. Lonial Phase 1/2 study of oral MLN9708, a novel, investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM) ASH Annual Meeting Abstracts 118 21 2011 479
60. D. Chauhan, T. Hideshima, and K.C. Anderson A novel proteasome inhibitor NPI-0052 as an anticancer therapy BrJCancer 95 8 2006 961 965
61. D. Chauhan, L. Catley, and G. Li A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib Cancer Cell 8 5 2005 407 419
62. D. Chauhan, A. Singh, and M. Brahmandam Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma Blood 111 3 2008 1654 1664
63. P.G. Richardson, A. Spencer, and P. Cannell Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM) ASH Annual Meeting Abstracts 118 21 2011 302
64. T. Ito, H. Ando, and T. Suzuki Identification of a primary target of thalidomide teratogenicity Science 327 5971 2010 1345 1350
65. Y.X. Zhu, E. Braggio, and C.X. Shi Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide Blood 118 18 2011 4771 4779
66. S. Li, R. Pal, and S.A. Monaghan IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM Blood 117 19 2011 5157 5165
67. A. Lopez-Girona, D. Heintel, and L.H. Zhang Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response Br J Haematol 154 3 2011 325 336
68. T. Hideshima, D. Chauhan, and Y. Shima Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96 9 2000 2943 2950
69. A.K. Gandhi, J. Kang, and L. Capone Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function Curr Cancer Drug Targets 10 2 2010 155 167
70. L. Escoubet-Lozach, I.L. Lin, and K. Jensen-Pergakes Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism Cancer Res 69 18 2009 7347 7356
71. D. Gupta, S.P. Treon, and Y. Shima Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications Leukemia 15 12 2001 1950 1961
72. D.H. Chang, N. Liu, and V. Klimek Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications Blood 108 2 2006 618 621
73. L. Wu, M. Adams, and T. Carter lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells Clin Cancer Res 14 14 2008 4650 4657
74. C. Galustian, B. Meyer, and M.C. Labarthe The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells Cancer Immunol Immunother 58 7 2009 1033 1045
75. A.G. Ramsay, A.J. Johnson, and A.M. Lee Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug J Clin Invest 118 7 2008 2427 2437
76. Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010;24 Suppl 1:S13-9
77. B. Barlogie, R. Desikan, and P. Eddlemon Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients Blood 98 2 2001 492 494
78. A. Glasmacher, C. Hahn, and F. Hoffmann A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma BrJHaematol 132 5 2006 584 593
79. J.-P. Fermand, A. Jaccard, and M. Macro A randomized comparison of dexamethasone + thalidomide (Dex/Thal) vs Dex + placebo (Dex/P) in patients (pts) with relapsing multiple myeloma (MM) ASH Annual Meeting Abstracts 108 11 2006 3563
80. R. Garcia-Sanz, J.R. Gonzalez-Porras, and J.M. Hernandez The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma Leukemia 18 4 2004 856 863
81. P. Moreau, H. Avet-Loiseau, and T. Facon Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma Blood 118 22 2011 5752 5758
82. L. Rosinol, A. Oriol, and A.I. Teruel Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study Blood 120 8 2012 1589 1596
83. P.M. Fayers, A. Palumbo, and C. Hulin Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials Blood 118 5 2011 1239 1247
84. G.J. Morgan, F.E. Davies, and W.M. Gregory Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation Blood 118 5 2011 1231 1238
85. P.G. Richardson, R.L. Schlossman, and E. Weller Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma Blood 100 9 2002 3063 3067
86. P.G. Richardson, E. Blood, and C.S. Mitsiades A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma Blood 108 10 2006 3458 3464
87. D.M. Weber, C. Chen, and R. Niesvizky Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl J Med 357 21 2007 2133 2142
88. M. Dimopoulos, A. Spencer, and M. Attal Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 21 2007 2123 2132
89. S. Knop, C. Gerecke, and P. Liebisch Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom) Blood 113 18 2009 4137 4143
90. G.J. Morgan, S.A. Schey, and P. Wu Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients Br J Haematol 137 3 2007 268 269
91. S.A. Schey, P. Fields, and J.B. Bartlett Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma J Clin Oncol 22 16 2004 3269 3276
92. M.J. Streetly, K. Gyertson, Y. Daniel, J.B. Zeldis, M. Kazmi, and S.A. Schey Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation Br J Haematol 141 1 2008 41 51
93. P.G. Richardson, D. Siegel, and R. Baz A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib ASH Annual Meeting Abstracts 116 21 2010 864
94. P.G. Richardson, D.S. Siegel, and R. Vij Randomized, open label phase 1/2 study of pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients (Pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT): phase 2 results ASH Annual Meeting Abstracts 118 21 2011 634
95. M.Q. Lacy, S.R. Hayman, and M.A. Gertz Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma J Clin Oncol 27 30 2009 5008 5014
96. J.R. Mikhael, S.R. Hayman, and K. Laumann Long term outcomes of pomalidomide and dexamethasone in patients with relapsed multiple myeloma: analysis 4 years after the original cohort ASH Annual Meeting Abstracts 118 21 2011 2942
97. M.A. Dimopoulos, C. Chen, and A. Spencer Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma Leukemia 23 11 2009 2147 2152
98. S. Madan, M. Lacy, and A. Dispenzieri Efficacy of retreatment with immunomodulatory compounds in patients receiving initial therapy for newly diagnosed multiple myeloma ASH Annual Meeting Abstracts 116 21 2010 1964
99. S. Madan, M.Q. Lacy, and A. Dispenzieri Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma Blood 118 7 2011 1763 1765
100. E.M. Ocio, D. Fernandez-Lazaro, and L. San-Segundo Reversibility of the resistance to lenalidomide and pomalidomide and absence of cross-resistance in a murine model of MM ASH Annual Meeting Abstracts 118 21 2011 134
101. M.Q. Lacy, S.R. Hayman, and M.A. Gertz Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) Leukemia 24 11 2010 1934 1939
102. M.Q. Lacy, B.R. LaPlant, and K. Laumann Pomalidomide and dexamethasone in relapsed myeloma: results of 225 patients treated in five cohorts over three years ASH Annual Meeting Abstracts 118 21 2011 3963
103. M.Q. Lacy, J.B. Allred, and M.A. Gertz Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease Blood 118 11 2011 2970 2975
104. X. Leleu, M. Attal, and B. Arnulf High response rates to pomalidomide and dexamethasone in patients with refractory myeloma, final analysis of IFM 2009-02 ASH Annual Meeting Abstracts 118 21 2011 812
105. X. Leleu, M. Attal, and P. Moreau Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009-02 ASH Annual Meeting Abstracts 116 21 2010 859
106. M.A. Dimopoulos, M.Q. Lacy, and P. Moreau Pomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory MM: a phase 3, multicenter, randomized, open-label study ASH Annual Meeting Abstracts 120 21 2012 LBA-6
107. A. Palumbo, A. Larocca, and V. Montefusco Pomalidomide cyclophosphamide and prednisone (PCP) treatment for relapsed/refractory multiple myeloma ASH Annual Meeting Abstracts 120 21 2012 446
108. T.M. Mark, A. Boyer, and A.C. Rossi ClaPD (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma ASH Annual Meeting Abstracts 120 21 2012 77
109. J.J. Shah, E.A. Stadtmauer, and R. Abonour A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma ASH Annual Meeting Abstracts 120 21 2012 74
110. D.S. diCapua Siegel, T. Martin, and M. Wang Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) ASH Annual Meeting Abstracts 116 21 2010 985
111. S. Kumar, W. Bensinger, and C.B. Reeder Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): a phase I study ASCO Meeting Abstracts 30 15 suppl 2012 8034
112. S. Lonial, R.C. Baz, and M. Wang Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM) ASCO Meeting Abstracts 30 15 suppl 2012 8017